Citations

Clear

590 citation(s) found for "Ho, Ben".

Architectural T-Wave Analysis and Identification of On-Therapy Breakthrough Arrhythmic Risk in Type 1 and Type 2 Long-QT Syndrome
Sugrue, Alan , Rohatgi, Ram K., Křemen, Václav , Bos, J. Martijn , Qiang, Bo , Sapir, Yehu , Brady, Peter A. , Asirvatham, Samuel J. , Friedman, Paul A. , Ackerman, Michael J. , Asirvatham, Samuel J , Kremen, Vaclav , Bos, Johan M , Noseworthy, Peter A. , Attia, Zachi I. , Scott, Christopher G.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | November 16, 2017 | Volume: 10 | Issue: 11 | Pages: No page available

10.1161/circep.117.005648 | PMID 29141844 Get It

Background: Although the hallmark of long-QT syndrome (LQTS) is abnormal cardiac repolarization, there are varying degrees of phenotypic expression and arrhythmic risk. Our aim was to evaluate the performance of a morphological T-wave analysis program in defining breakthrough LQTS arrhythmic risk beyond the QTc value. Methods and Results: We analyzed 407 genetically confirmed patients with LQT1 (n=246; 43% men) and LQT2 (n=161; 41% men) over the mean follow-up period of 6.4±3.9 years. ECG analysis was conducted using a novel, proprietary T-wave analysis program. Time to a LQTS-associated cardiac event was analyzed using Cox proportional hazards regression methods. Twenty-three patients experienced ≥1 defined breakthrough cardiac arrhythmic events with 5- and 10-year event rates of 4% and 7%. Two independent predictors of future LQTS-associated cardiac events from the surface ECG were identified: left slope of T wave in lead V6 (hazard ratio=0.40 [0.24–0.69]; P <0.001) and T-wave center of gravity x axis (last 25% of wave) in lead I (hazard ratio=1.90 [1.21–2.99]; P =0.005), C statistic of 0.77 (0.65–0.89). When added to the QTc (C statistic 0.68 for QTc alone), discrimination improved to 0.78. Genotype analysis showed weaker association between these T-wave variables and LQT1-triggered events while these features were stronger in patients with LQT2 and significantly outperformed the QTc (C statistic, 0.82 [0.71–0.93]). Conclusion: Detailed morphological analysis of the T wave provides novel insights into risk of breakthrough arrhythmic events in LQTS, particularly LQT2. This observation has the potential to guide clinical decision making and further refine risk stratification.
Ureteroscopic Laser Lithotripsy: A Review of Dusting vs Fragmentation with Extraction
Matlaga, Brian R., Eisner, Brian H. , Humphreys, Mitchell R. , Knudsen, Bodo E. , Krambeck, Amy E. , Lange, Dirk , Lipkin, Michael E. , Miller, Nicole L. , Monga, Manoj, Pais, Vernon M., Sur, Roger L. , Shah, Ojas , Humphreys, Mitchell, Krambeck, Amy, Chew, Ben H. , Miller, Nicole L

Mayo Clinic

Journal of Endourology | October 24, 2017 | Volume: 32 | Issue: 1 | Pages: 1-6

10.1089/end.2017.0641 | PMID 29061070 Get It

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Avet‐Loiseau, Hervé , Masszi, Tamás , Viterbo, Luísa, Pour, Luděk, Palumbo, Antonio , Cavo, Michèle , Langer, Christian , Pluta, Andrzej, Nagler, Arnon , Kumar, Shaji , Ben‐Yehuda, Dina, Miguel, Jesús F. San , Berg, Deborah, Lin, Jianchang , Velde, Helgi van de , Esseltine, Dixie‐Lee, Bacco, Alessandra Di , Moreau, Philippe , Richardson, Paul G. , Moreau, Philippe , San-Miguel, Jesus , Masszi, Tamas , Bahlis, Nizar Jacques , Chng, Wee Joo , Ganly, Peter S. , Rajkumar, S. Vincent , Esseltine, Dixie‐Lee, Richardson, Paul Gerard Guy

Mayo Clinic

Blood | October 20, 2017 | Volume: 130 | Issue: 24 | Pages: 2610-2618

10.1182/blood-2017-06-791228 | PMID 29054911 Get It

Key Points IRd was associated with a consistent PFS benefit vs placebo-Rd in RRMM patients with high-risk and standard-risk cytogenetics. The addition of ixazomib to Rd overcomes the poor PFS associated with high-risk cytogenetics in patients with RRMM.
Minimal toxicity after proton beam therapy for prostate and pelvic nodal irradiation: results from the proton collaborative group REG001-09 trial
Chuong, Michael D. , Hartsell, William F. , Larson, Gary, Laramore, George E. , Rossi, Carl J., Wilkinson, J. Ben, Kaiser, Adeel , Vargas, Carlos , Tsai, Henry K.

Mayo Clinic

Acta Oncologica | October 14, 2017 | Volume: 57 | Issue: 3 | Pages: 368-374

10.1080/0284186x.2017.1388539 | PMID 29034790 Get It

Randomized Controlled Trial Comparing Three Different Modalities of Lithotrites for Intracorporeal Lithotripsy in Percutaneous Nephrolithotomy
York, Nadya , Borofsky, Michael S. , Dauw, Casey A. , Paterson, Ryan F. , Denstedt, John D. , Razvi, Hassan , Nadler, Robert B., Humphreys, Mitchell R. , Preminger, Glenn M. , Nakada, Stephen Y., Krambeck, Amy E. , Miller, Nicole L. , Terry, Colin, Rawlings, Lori D., Lingeman, James E., Chew, Ben H. , Miller, Nicole L

Mayo Clinic

Journal of Endourology | September 1, 2017 | Volume: 31 | Issue: 11 | Pages: 1145-1151

10.1089/end.2017.0436 | PMID 28859485 Get It

Abstract 1315: Estimating sex-specific effects of genetic loci associated with glioma risk
Kinnersley, Ben , Wrensch, Margaret , Eckel‐Passow, Jeanette E. , Armstrong, Georgina , Rice, Terri, Wiencke, John, McCoy, Lucie , Hansen, Helen M. , Bernstein, Jonine L. , Claus, Elizabeth B. , Johansen, Christoffer , Lai, Rose , Lau, Ching C. , Merrell, Ryan , Sadetzki, Siegal, Schildkraut, Joellen, Shete, Sanjay , Houlston, Richard S. , Jenkins, Robert B. , Melin, Beatrice , Ostrom, Quinn T. , Armstrong, Georgina , Chen, Yanwen , Wiencke, John K. , Amos, Christopher I. , Il’yasova, Dora , Lachance, Daniel Honore , Olson, Sara H. , Bondy, Melissa L. , Barnholtz‐Sloan, Jill S. , Houlston, Richard S

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 1315-1315

10.1158/1538-7445.am2017-1315 Get It

Abstract BACKGROUND: Incidence of glioma varies significantly by sex, and most glioma histologies occur with greater incidence in males. Previous analyses have examined the impact of estrogen exposure as a risk factor for these tumors, but have found results of varying significance and low effect size. There may be differences in effect of previously discovered risk alleles that contribute to sex differences. METHODS: Using data collected for three previous glioma GWAS in European-ancestry populations (MD Anderson Cancer Center, the San Francisco Adult Glioma Study, and the Glioma International Case Control Study) we assessed sex-specific effects for 14 previously identified and 13 newly identified glioma risk SNPs (27 total) overall and for glioblastoma (GBM) and non-GBM tumors separately. There were 3,892 male cases (59% GBM), 4,522 male controls, 2,500 female cases (52% GBM) and 4,940 female controls. Sex-specific odds ratios (ORM and ORF), 95% confidence intervals (95% CI) and p values (pM and pF) were generated using stratified logistic regression models. Data from each study were analyzed separately and combined using inverse variance weighted meta-analysis. Results were considered statistically significant at p&lt;6.2x10-4. RESULTS: In GBM, rs11979158 (7p11.2, pM=1.01x10-10, ORM=1.43 [95% CI: 1.28-1.59]; pF=3.43x10-3, ORF=1.22 [95% CI: 1.07-1.39]) and rs2562152 (16p13.3, pM=5.59x10-4, ORM=1.23 [95% CI: 1.09-1.39]; pF=1.22x10-1, ORF=1.12 [95% CI: 0.97-1.29]) had significant effect in males only. In non-GBM gliomas, rs12076373 (1q44, pM=3.56x10-7, ORM=1.41, 95% CI: 1.23-1.61; pF=1.76x10-2, ORF=1.20, 95% CI: 1.03-1.38), rs11979158 (7p11.2, pM=1.77x10-5, ORM=1.32 [95% CI: 1.16-1.49]; pF=2.73x10-1, ORF=1.08 [95% CI: 0.94-1.24]), and rs3751667 (16p13.3, pM=9.44x10-7, ORM=1.30 [95% CI: 1.17-1.44]; pF=5.18x10-2, ORF=1.13 [95% CI: 1.00-1.28]) had significant effect in males only. Effect size for rs55705857 (8q24.21) varied significantly by sex, with ORM=2.63 (95% CI: 2.24-3.09, pM=4.42x10-32), as compared to ORF=3.95 (95% CI: 3.28-4.76, pF=1.82x10-47). A sensitivity analysis was performed due to allele frequency heterogeneity by study and results did not change. CONCLUSIONS: Sex differences and other demographic differences in cancer susceptibility can provide important clues to etiology, and these differences can be leveraged for discovery in genetic association studies. Significant differences in effect size may suggest variation in genetic effect of risk alleles or in unidentified risk factors that vary in prevalence or effect by sex. There may also be differences in the distribution of molecular subtypes within each histology by sex. Further investigation using an agnostic approach may further elucidate the relationship between effect of risk alleles and sex. Citation Format: Quinn T. Ostrom, Ben Kinnersley, Margaret Wrensch, Jeanette E. Eckel-Passow, Georgina Armstrong, Terri Rice, Yanwen Chen, John Wiencke, Lucie McCoy, Helen Hansen, Christopher Amos, Jonine L. Bernstein, Elizabeth B. Claus, Dora Il'yasova, Christoffer Johansen, Daniel Lachance, Rose Lai, Ching C. Lau, Ryan T. Merrell, Sara H. Olson, Siegal Sadetzki, Joellen Schildkraut, Sanjay Shete, Richard S. Houlston, Robert B. Jenkins, Beatrice Melin, Melissa Bondy, Jill S. Barnholtz-Sloan. Estimating sex-specific effects of genetic loci associated with glioma risk [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1315. doi:10.1158/1538-7445.AM2017-1315
Abstract 1302: Genome-wide association study of glioma reveals specific differences in genetic susceptibility to glioblastoma and non-glioblastoma
Kinnersley, Ben , Melin, Beatrice , Wrensch, Margaret , Johansen, Christoffer , Ostrom, Quinn T. , GICC, and members of, Labrèche, Karim , Eckel‐Passow, Jeanette E. , Decker, Paul A. , Labussière, Marianne, Delattre, Jean‐Yves, Gousias, Konstantinos , Schramm, Johannes, Schoemaker, Minouk J. , Nöthen, Marcus M., Wichmann, Heinz‐Erich, Lathrop, Mark, Simon, Matthias , Chanock, Stephen, Linet, Martha S. , Lai, Rose , Claus, Elizabeth B. , Jenkins, Robert B. , Houlston, Richard S. , Barnholtz‐Sloan, Jill S. , Il’yasova, Dora , GICC, and members of, Decker, Paul A. , Idbaïh, Ahmed , Hoang‐Xuan, Khê , Stefano, Anna Luisa Di , Mokhtari, Karima , Galán, Pilar , Fleming, Sarah , Herms, Stefan , Heilmann‐Heimbach, Stefanie , Schreiber, Stefan , Swerdlow, Anthony J. , Sanson, Marc , Rajaraman, Preetha , Wang, Zhaoming , Yeager, Meredith , Olson, Sara H. , Bondy, Melissa L. , Houlston, Richard S , Schoemaker, Minouk J , Ostrom, Quinn T

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 1302-1302

10.1158/1538-7445.am2017-1302 Get It

Abstract BACKGROUND: Glioma accounts for ~27% of all primary brain tumors and is responsible for ~13,000 cancer-related deaths in the US each year. Glioma tumors can be broadly classified into glioblastoma (GBM) and lower-grade non-GBM. Typically gliomas have a poor prognosis irrespective of medical care, with the most common form, GBM, having a five-year survival rate of only 5%. While genome-wide association studies (GWAS) have transformed our understanding of glioma susceptibility, individual studies have had limited power to identify risk loci. METHODS: We performed the largest glioma GWAS to date, comprising a meta-analysis of six existing GWAS (6,405 cases, 14,100 controls) as well as new GWAS from the Glioma International Case Control Consortium (GICC; 4,572 cases and 3,286 controls) and University of California, San Francisco (UCSF)-Mayo (1,519 cases, 804 controls), totaling 12,496 cases (6,191 classified as GBM, 5,819 as non-GBM) and 18,190 controls. RESULTS: We identified five new risk loci for GBM at 1p31.3 (rs12752552; near JAK1, P=2.04×10-9, odds ratio (OR)=1.22), 11q14.1 (rs11233250; P=9.95×10-10, OR=1.24), 16p13.3 (rs2562152; near MPG, P=1.93x10-8, OR=1.21), 16q12.1 (rs10852606; HEATR3, P=1.29×10-11, OR=1.18), 22q13.1 (rs2235573; P=1.76×10-10, OR=1.15) and eight for non-GBM at 1q32.1 (rs4252707; MDM4, P=3.34×10-9, OR=1.19), 1q44 (rs12076373; AKT3, P=2.63×10-10, OR=1.23), 2q33.3 (rs7572263; near IDH1, P=2.18×10-10, OR=1.20), 3p14.1 (rs11706832; LRIG1, P=7.66×10-9, OR=1.15), 10q24.33 (rs11598018; OBFC1, P=3.39×10-8, OR=1.14), 11q21 (rs7107785; P=3.87×10-10, OR=1.16), 14q12 (rs10131032; P=5.07x10-11, OR=1.33) and 16p13.3 (rs3751667; P=2.61×10-9, OR=1.18). Case-only analyses confirmed the specificity of 11q14.1, 16p13.3 and 22q13.1 associations for GBM and 1q44, 2q33.3, 3p14.1, 11q21 and 14q12 for non-GBM tumors. In the combined meta-analysis, among previously published glioma risk SNPs, those for all glioma at 17p13.1 (TP53), GBM at 5p15.33 (TERT), 7p11.2 (EGFR), 9p21.3 (CDKN2B-AS1) and 20q13.33 (RTEL1) and for non-GBM at 8q24.21 (CCDC26), 11q23.2, 11q23.3 (PHLDB1) and 15q24.2 (ETFA) showed even greater evidence for association. SNPs at 10q25.2 and 12q12.1 for non-GBM tumors retained genome-wide significance (i.e. P&lt;5.0x10-8). Associations at the previously reported loci for GBM at 3q26.2 (near TERC) and 12q23.33 (POLR3B) did not retain statistical significance. CONCLUSIONS: Our findings substantiate genetic susceptibility to GBM and non-GBM glioma being highly distinct, consistent with their distinctive molecular profiles presumably resulting from different etiological pathways. Functional analyses should lead to further insights into the biological basis of the different glioma histologies. Such information can inform gene discovery initiatives and therefore have a measurable impact on the successful development of new therapeutic agents. Citation Format: Ben Kinnersley, Beatrice S. Melin, Jill S. Barnholtz-Sloan, Margaret R. Wrensch, Christoffer Johansen, Dora Il’yasova, Quinn Ostrom, and members of GICC, Karim Labreche, Jeanette E. Eckel-Passow, Paul A. Decker, Marianne Labussière, Ahmed Idbaih, Khe Hoang-Xuan, Anna-Luisa Di Stefano, Karima Mokhtari, Jean-Yves Delattre, Pilar Galan, Konstantinos Gousias, Johannes Schramm, Minouk J. Schoemaker, Sarah J. Fleming, Stefan Herms, Stefanie Heilmann, Marcus M. Nöthen, Heinz-Erich Wichmann, Stefan Schreiber, Anthony Swerdlow, Mark Lathrop, Matthias Simon, Marc Sanson, Preetha Rajaraman, Stephen Chanock, Martha Linet, Zhaoming Wang, Meredith Yeager, Rose K. Lai, Elizabeth B. Claus, Sara H. Olson, Robert B. Jenkins, Richard S. Houlston, Melissa L. Bondy. Genome-wide association study of glioma reveals specific differences in genetic susceptibility to glioblastoma and non-glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1302. doi:10.1158/1538-7445.AM2017-1302
Solar insolation in springtime influences age of onset of bipolar I disorder
Bauer, Michael , Glenn, Tasha , Aleksandrovich, M. A., Angelopoulos, Elias, Ardau, Raffaella , Ayhan, Yavuz , Baethge, Christopher , Bharathram, S. R., Bauer, Rita, Becerra‐Palars, C., Belmaker, Robert H. , Berk, Michael , Bersudsky, Yuly, Bicakci, Ş., Bjella, Thomas , Bossini, Letizia, Cabrera, Jorge , Cheung, Eric Yat Wo, Zompo, Maria Del , Donix, Markus , Étain, Bruno , Fountoulakis, Konstantinos Ν. , Frye, Mark A. , González‐Pinto, Ana , Gottlieb, John F. , Grof, Paul , Harima, Hirohiko, Henry, Chantal , Isometsä, Erkki , Janno, Sven , Kapczinski, Flávio , Kardell, Mathias, Khaldi, S., Kliwicki, Sebastian , Kot, Timur L., Krogh, Rikke, Kunz, Maurício , Lafer, Beny , Landén, Mikael , Larsen, Erik Roj , Lewitzka, Ute , Licht, Rasmus Wentzer , López‐Jaramillo, Carlos , Manchia, Mirko , Marsh, Wendy , Melle, Ingrid , Meza-Urzúa, Fátima, Ming, Mok Yee, Monteith, Scott , Morken, Gunnar , Mosca, Enrica, Muñoz, Rodrigo , Mythri, Starlin Vijay , Nacef, F., Nery, Fabiano G. , Nielsen, René Ernst , O’Donovan, Claire , Omrani, Adel, Osher, Yamima , Sørensen, Helle Østermark , Ouali, Uta , Ruiz, Yolanda Pica, Pilhatsch, Maximilian , Pinna, Marco , Ponte, Francisco Diego Rabelo da, Quiroz, Danilo , Ramesar, Raj , Rasgon, Natalie , Reddy, M. S., Reif, Andreas , Ritter, Philipp , Sagduyu, Kemal, Scippa, Ângela Miranda, Severus, Emanuel , Simhandl, Christian , Stein, Dan J. , Strejilevich, Sergio , Sulaiman, Ahmad Hatim , Suominen, Kirsi, Tagata, Hiromi , Tatebayashi, Yoshitaka , Vaaler, A. E., Veeh, Julia, Vieta, Eduard , Viswanath, Biju , Yoldi‐Negrete, María , Zetin, Mark, Zgueb, Yosra , Whybrow, Peter C., Bauer, M , Bellivier, F , Etain, B , Vieta, E , Alda, Martin , Andreassen, Ole A. , Baune, Bernhard , Bellivier, Frank , Bicakci, Ş., Birabwa‐Oketcho, Harriet , Dodd, Seetal , Fagiolini, Andrea , König, Barbara , MacQUEEN, GLENDA M. , Martínez‐Cengotitabengoa, Mónica , MUNOZ, RODRIGO A. , Nadella, R K , Rybakowski, Janusz K , Subramaniam, M , Tondo, Leonardo , Torrent, Carla , Vaaler, A. E., Stein, Dan J , López-Jaramillo, Carlos , Fountoulakis, Konstantinos N , Reif, Andreas , Viswanath, Biju , Berk, Michael , Manchia, Mirko , Ouali, U , Ritter, P , Strejilevich, S , Yoldi-Negrete, M , Bıçakcı, Şule

Mayo Clinic

Acta Psychiatrica Scandinavica | July 19, 2017 | Volume: 136 | Issue: 6 | Pages: 571-582

10.1111/acps.12772 | PMID 28722128 Get It

ObjectiveTo confirm prior findings that the larger the maximum monthly increase in solar insolation in springtime, the younger the age of onset of bipolar disorder.MethodData were collected from 5536 patients at 50 sites in 32 countries on six continents. Onset occurred at 456 locations in 57 countries. Variables included solar insolation, birth‐cohort, family history, polarity of first episode and country physician density.ResultsThere was a significant, inverse association between the maximum monthly increase in solar insolation at the onset location, and the age of onset. This effect was reduced in those without a family history of mood disorders and with a first episode of mania rather than depression. The maximum monthly increase occurred in springtime. The youngest birth‐cohort had the youngest age of onset. All prior relationships were confirmed using both the entire sample, and only the youngest birth‐cohort (all estimated coefficientsP< 0.001).ConclusionA large increase in springtime solar insolation may impact the onset of bipolar disorder, especially with a family history of mood disorders. Recent societal changes that affect light exposure (LEDlighting, mobile devices backlit withLEDs) may influence adaptability to a springtime circadian challenge.
Prognostic implications of Q waves at presentation in patients with ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An analysis of the HORIZONS‐AMI study
Kosmidou, Ioanna , Redfors, Björn , Crowley, Aaron , Dizon, José , Embacher, Monica, Ben‐Yehuda, Ori , Mintz, Gary S. , Stone, Gregg W. , Gersh, Bernard J. , Chen, Shmuel , Mehran, Roxana

Mayo Clinic

Clinical Cardiology | July 11, 2017 | Volume: 40 | Issue: 11 | Pages: 982-987

10.1002/clc.22751 | PMID 28696573 Get It

BackgroundPresence of Q waves on the presenting electrocardiogram (ECG) in patients with ST‐segment elevation myocardial infarction (STEMI) has been associated with worse prognosis; however, whether the prognostic value of Q waves is influenced by baseline characteristics and/or rapidity of revascularization based on the guideline‐based metric of door‐to‐balloon time remains unknown.HypothesisWe hypothesized that Q waves in the presenting ECG will be predictive of long term mortality regardless of time to reperfusion.MethodsThe Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS‐AMI) trial enrolled 3602 patients with STEMI undergoing primary percutaneous coronary intervention. We stratified patients without prior history of myocardial infarction or coronary revascularization according to presence or absence of pathological Q waves on their presenting ECG. Associations between Q waves, death, and cardiovascular outcomes within 3 years were assessed using Cox proportional hazards regression.ResultsAmong 2723 patients with evaluable ECGs, 1084 (39.8%) had Q waves on their presenting ECG. Male sex and time from symptom onset to balloon inflation were independent predictors of presence of Q waves. Patients with Q waves had higher adjusted risks of all‐cause death (adjusted hazard ratio: 1.45, 95% confidence interval: 1.02‐2.05, P = 0.04) and cardiac death (adjusted hazard ratio: 1.72, 95% confidence interval: 1.08‐2.72, P = 0.02). The association between Q waves and cardiac death was consistent regardless of sex, diabetes status, target vessel, or door‐to‐balloon time (Pinteraction > 0.4 for all).ConclusionsPresence of Q waves on the presenting ECG in patients undergoing primary percutaneous coronary intervention due to STEMI is an independent predictor of mortality and adds prognostic value, regardless of sex or rapidity of revascularization.